Vivos Therapeutics Inc.
Find Ratings ReportsVIVOS THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. VIVOS THERAPEUTICS INC has very weak liquidity. Currently, the Quick Ratio is 0.17 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 99.53% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY23 | Q3 FY22 |
---|---|---|
Net Sales ($mil) | 3.3 | 4.25 |
EBITDA ($mil) | -3.34 | -5.23 |
EBIT ($mil) | -3.49 | -5.41 |
Net Income ($mil) | -2.09 | -5.43 |
Balance Sheet | Q3 FY23 | Q3 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 0.99 | 6.72 |
Total Assets ($mil) | 10.32 | 18.4 |
Total Debt ($mil) | 2.1 | 2.85 |
Equity ($mil) | 0.05 | 9.86 |
Profitability | Q3 FY23 | Q3 FY22 |
---|---|---|
Gross Profit Margin | 57.48 | 58.78 |
EBITDA Margin | -101.27 | -123.19 |
Operating Margin | -105.79 | -127.34 |
Sales Turnover | 1.41 | 0.9 |
Return on Assets | -149.39 | -136.67 |
Return on Equity | -33506.52 | -255.19 |
Debt | Q3 FY23 | Q3 FY22 |
---|---|---|
Current Ratio | 0.28 | 1.63 |
Debt/Capital | 0.98 | 0.22 |
Interest Expense | 0.0 | 0.0 |
Interest Coverage | 0.0 | 0.0 |
Share Data | Q3 FY23 | Q3 FY22 |
---|---|---|
Shares outstanding (mil) | 1.2 | 0.92 |
Div / share | 0.0 | 0.0 |
EPS | -1.75 | -6.5 |
Book value / share | 0.04 | 10.71 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 152170.0 | 5556922.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 110.87 indicates a significant premium versus the S&P 500 average of 4.68 and a significant premium versus the subsector average of 4.51. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, VIVOS THERAPEUTICS INC proves to trade at a premium to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VVOS NM | Peers 133.57 | VVOS NM | Peers 23.80 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. VVOS's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. VVOS's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
VVOS NM | Peers 36.89 | VVOS NA | Peers 0.97 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. VVOS's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
VVOS 110.87 | Peers 4.51 | VVOS 54.32 | Peers 106.52 | |||||||||||||||||||||
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. VVOS is trading at a significant premium to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, VVOS is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
VVOS 0.35 | Peers 5.18 | VVOS -11.94 | Peers 25.26 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. VVOS is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. VVOS significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||